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Abstract 26 
Modifiers of Mendelian disorders can provide insights into disease mechanisms and guide 27 
therapeutic strategies. A recent genome-wide association (GWA) study discovered genetic modifiers of 28 
Huntington's disease (HD) onset in Europeans. Here, we performed whole genome sequencing and 29 
GWA analysis of a Venezuelan HD cluster whose families were crucial for the original mapping of the 30 
HD gene defect. The Venezuelan HD subjects develop motor symptoms earlier than their European 31 
counterparts, implying the potential for population-specific modifiers. The main Venezuelan HD family 32 
inherits HTT haplotype hap.03, which differs subtly at the sequence level from European HD hap.03, 33 
suggesting a different ancestral origin but not explaining the earlier age at onset in these Venezuelans. 34 
GWA analysis of the Venezuelan HD cluster suggests both population-specific and population-shared 35 
genetic modifiers. Genome-wide significant signals at 7p21.2-21.1 and suggestive association signals 36 
at 4p14 and 17q21.2 are evident only in Venezuelan HD, but genome-wide significant association 37 
signals at the established European chromosome 15 modifier locus are improved when Venezuelan HD 38 
data are included in the meta-analysis. Venezuelan-specific association signals on chromosome 7 39 
center on SOSTDC1, which encodes a bone morphogenetic protein antagonist. The corresponding 40 
SNPs are associated with reduced expression of SOSTDC1 in non-Venezuelan tissue samples, 41 
suggesting that interaction of reduced SOSTDC1 expression with a population-specific genetic or 42 
environmental factor may be responsible for modification of HD onset in Venezuela. Detection of 43 
population-specific modification in Venezuelan HD supports the value of distinct disease populations in 44 
revealing novel aspects of a disease and population-relevant therapeutic strategies. 45 
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Author summary 46 
Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder caused by a 47 
CAG trinucleotide expansion in HTT, which encodes huntingtin. HD involves various neurological 48 
manifestations such as involuntary movements, cognitive decline, and personality change; age at onset 49 
of diagnostic signs is partly determined by the length of the CAG repeat. However, genome-wide 50 
analysis of European HD subjects revealed that age at onset corrected for individual CAG repeat size is 51 
modified by other genetic factors, revealing potential disease-delaying pathways that form targets for 52 
therapeutic strategies. In this study, we set out to identify genetic modifiers in a Venezuelan HD cluster 53 
whose families were crucial for discovering the cause of HD. Through genome-wide association 54 
analysis using age at onset corrected for CAG repeat size as the phenotype, we found genome-wide 55 
significant (chromosome 7) and suggestive significant association signals (chromosomes 4 and 17). 56 
Significant modification signals in Venezuelan HD appear to be population-specific because genetic 57 
analysis of European HD subjects did not reveal modification signals at those locations. Nevertheless, 58 
established modification signals in European HD at a chromosome 15 locus were also augmented by 59 
Venezuelan HD data, supporting the existence of both shared and population-specific genetic modifiers 60 
in HD. Together with the full sequence of HTT shared by the majority of these Venezuelan HD subjects, 61 
our genetic analysis provides insights into the geographical origin of the founder mutation, meaningful 62 
allele-specific sites for gene targeting approaches, and potential targets for disease-modifying 63 
intervention in this population.  64 
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Introduction 65 
Huntington's disease (HD; MIM 143100), a familial neurodegenerative disorder characterized by 66 
progressive movement disorder, cognitive decline, and psychiatric disturbances, is caused by an 67 
expanded CAG glutamine codon repeat in HTT, which encodes huntingtin [1-3]. This genetic defect 68 
was originally mapped to chromosome 4p16.3 using linkage analysis in part in Venezuelan families 69 
from an HD population cluster whose generous participation in this fundamental HD genetic research 70 
also contributed, along with many North American and European families also carrying a CAG 71 
expansion mutation, to the discovery of HTT [3-6]. The HTT repeat is polymorphic in the normal 72 
population [7], but inheritance of >35 CAGs can lead to HD, while repeats of >40 CAGs are fully 73 
penetrant within a normal lifespan [8,9]. Expanded repeats show frequent germline instability so that 74 
HD individuals may not have a CAG repeat length identical to their transmitting parent [10-12]. Rare de 75 
novo cases of HD are generated sporadically in the population by intergenerational expansion of a 76 
normal length CAG repeat [13,14]. The length of the inherited HTT CAG repeat is the primary 77 
determinant of the age at onset of diagnostic neurological signs, accounting for ~65% of the variance in 78 
this phenotype, with longer repeats leading on average to earlier clinical manifestations [7,15-18]. 79 
Individuals with biallelic HD mutations (i.e., HD homozygotes) have been reported and support 80 
complete dominance with respect to the pathogenic mechanism leading to disease manifestations 81 
since the age at onset of an individual with two expanded HTT CAG repeats is comparable to that of a 82 
heterozygote with the longer of the two repeats [7,19]. Interestingly, based upon one report, despite an 83 
age at onset similar to HD heterozygotes, individuals with two expanded HTT CAG repeats may display 84 
more rapid decline in functional capacity [20]. Although the timing of disease onset is CAG repeat size-85 
dependent, the duration of manifest disease (i.e., the length of time from onset to death) is not [21], 86 
suggesting that progression to death involves different tissues or mechanisms than those leading to 87 
clinical onset. The relationship between CAG repeat size and HD clinical onset has played an important 88 
role in guiding 1) the generation of animal models [22-26], 2) design/interpretation of molecular studies 89 
[27], and 3) identification of genetic modifiers [28].  90 
The extensive accumulated experimental data and complete dominance of the mutant allele are 91 
most consistent with a gain-of-function mechanism, which has prompted exploration of mutant allele-92 
 5
specific interference with HTT expression as a treatment option [29]. Although highly promising in 93 
model systems, gene-targeting approaches are just now beginning human trials of safety and efficacy. 94 
An alternative strategy for the identification of therapeutic targets is to capitalize on observations from 95 
humans with HD to discover naturally occurring modifiers of disease. Although CAG length accounts for 96 
a significant proportion of the variance in HD age at onset [15,16,18], each CAG repeat size in the HD 97 
population is associated with a wide range of onset ages [7]. Since individual differences between the 98 
observed age at clinical onset and the age at clinical onset expected based upon the size of the 99 
mutation (i.e., residual age at onset) are partially heritable [30,31], both genetic and environmental 100 
factors are thought to influence the timing of onset in addition to CAG length [32]. The HD-associated 101 
CAG expansion sits on diverse haplotypes [33-38], reflecting multiple independent mutation events on 102 
different polymorphic chromosome backbones. However, none of the most frequent disease 103 
chromosome haplotypes is associated with a difference in age at onset [34], arguing that HD is not 104 
commonly modified by a common cis genetic factor at HTT. Similarly, age at diagnostic motor onset of 105 
HD is not influenced by the length of the normal CAG repeat [7,32], or by the presence of a second 106 
mutant allele [7], suggesting that heritable variance in age at onset for a given CAG repeat is largely 107 
due to unlinked trans factors [39]. To identify these, we performed an initial genome-wide association 108 
(GWA) analysis in HD subjects of European descent that revealed the first set of genome-wide 109 
significant loci associated with residual age at onset of motor symptoms. Briefly, there were two 110 
independent onset modification signals on chromosome 15 [28], one modification signal on 111 
chromosome 8 [28], and one modification signal on chromosome 3 [40]. Two of the modifier loci acted 112 
to delay onset and two acted to hasten onset [28,40,41]. These findings established the proof-of-113 
principle that the pathogenesis of HD can be altered prior to emergence of clinical disease. Consistent 114 
with single SNP analysis results, pathway analysis supported a role for DNA repair/maintenance 115 
pathways in modifying the age at onset of HD, suggesting that somatic size changes of the CAG repeat 116 
may play a role in modification of the HD pathogenic process that leads to diagnostic clinical signs [28]. 117 
Together, these observations demonstrated that genetic factors in humans are capable of modifying the 118 
rate of HD pathogenesis prior to diagnosis and point to an approach based upon such human 119 
observations for therapeutic targeting to delay HD onset.  120 
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Most genome-wide analyses to date have focused on Europeans, providing important but 121 
potentially limited insights into the genetic contribution to disease risk and normal traits (GWAS 122 
Catalog; https://www.ebi.ac.uk/gwas/). Our initial European HD GWA study [28] was highly successful 123 
in revealing significant modifier loci of relatively strong effect based upon a smaller sample size than 124 
most common disease genetic risk studies (GWAS Catalog; https://www.ebi.ac.uk/gwas/). However, we 125 
might have missed genetic modifiers not present in Europeans. Here, we have extended our genetic 126 
analysis to the Venezuelan HD cluster of non-European HD subjects to: 1) determine the full sequence 127 
of HTT on the chromosome bearing the CAG expansion mutation; 2) to investigate its origin, and 3) to 128 
determine whether modification of age at onset in this Venezuelan population is associated with 129 




Venezuelan HD subjects 133 
From 1979 to 1999, an interdisciplinary team of investigators annually visited Venezuela to 134 
solicit the participation of a large cluster of HD families in research, to document their disease and to 135 
obtain blood samples for DNA analysis and preparation of lymphoblastoid cell lines, which were banked 136 
for future studies. These HD families contributed to both the localization of the HD defect to 137 
chromosome 4 and to discovery of HTT and its expanded CAG repeat mutation [3-6]. In 2004, a 138 
publication summarizing more than two decades of work by the U.S.–Venezuela Collaborative 139 
Research Project described this HD cluster and presented evidence for both genetic and environmental 140 
modifiers of HD [30]. For the current study, we prepared DNA from lymphoblastoid cell lines banked 141 
prior to 1999 that had relevant clinical and/or relationship information recorded. In all, we genotyped 142 
443 HD and 106 related non-HD Venezuelan subjects using the Illumina Omni2.5 array platform [28] 143 
and performed genome-wide imputation using the Michigan Imputation Server 144 
(https://imputationserver.sph.umich.edu/index.html) with 1000 Genomes Project data (mixed 145 
population) as the reference panel. After quality control (QC) analysis, 374 HD subjects carrying adult 146 
onset HD CAG repeat sizes (CAG 40-55) with recorded age at onset of motor symptoms were analyzed 147 
in this study. Ancestry of subjects was characterized by comparing to 1000 Genomes Project data (S1 148 
Fig; open black squares represent Venezuelan study subjects), which confirmed the strongest similarity 149 
with Columbians (pink square) and Puerto Ricans (pink cross). In addition, familial relationships were 150 
inferred based upon estimated IBD from the genome-wide genotype data (S2 Fig), revealing that 151 
subjects were from 22 families of quite variable size (S3 Fig). The largest family, arbitrarily termed 152 
Family 1, comprised 218 HD individuals with the HD mutation on hap.03, which matches the third most 153 
frequent disease chromosome in European HD subjects (S3 Fig) [34,38]. Many of the smaller families 154 
(e.g., Family 6 and Family 12) also carry hap.03 and appear to be distantly related to members of the 155 
main family, consistent with pedigree reconstruction by the U.S.-Venezuela Collaborative Research 156 
Project (S3 Fig). However, the expanded HTT CAG repeats in some smaller families occur on different 157 
HTT haplotypes, including hap.01 (the most frequent European HD haplotype), hap.02, hap.06, hap.07 158 
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and hap.12 [34,38], indicating that most but not all HD chromosomes in the Venezuelan cluster are 159 
ancestrally related.  160 
 161 
Earlier age at onset in Venezuelan HD subjects 162 
The mean CAG sizes across all haplotypes among the Venezuelans were 45.9 and 19 for 163 
longer and shorter alleles, respectively, and the average age at onset was 35.5 (S4 Fig). The expected 164 
decrease in onset age with increasing repeat length was readily observed in this data set (Fig 1A). 165 
Notably, 12 subjects carried two expanded alleles (Fig 1A; red circles), and, as predicted from our 166 
previous European-based analysis [7], their ages at onset were best explained by the longer allele in 167 
each individual (Fig 1A; shorter allele p-value in a regression analysis, 0.111), supporting full 168 
dominance. Interestingly, as noted previously [32], the age at onset of Venezuelan HD subjects was 169 
distinctly earlier than that in European HD subjects (Fig 1B; ~5 years earlier). While such a difference 170 
could theoretically occur due to systematic biases in calling motor onset in different countries/study 171 
populations, we believe this is unlikely because the Venezuelan HD subjects show a disease duration 172 
(the time interval between onset and death, which is CAG-independent) indistinguishable from 173 
European HD (Fig 1C; Wilcoxon test p-value=0.2783) [21]. The consistency of mean disease duration 174 
across populations [21,42] argues that the earlier disease diagnosis for Venezuelan HD subjects does 175 
not represent a systematic calling of the diagnosis earlier in the disease process, which would result in 176 
longer durations, but rather truly reflects a more rapid CAG-dependent disease pathogenesis leading to 177 
motor onset. 178 
Among European HD subjects, residual age at onset (i.e., observed age at diagnostic motor 179 
onset minus expected age at onset based on individual CAG repeat size) was not different between HD 180 
subjects carrying different common haplotypes [34], and the HTT locus did not emerge as associated 181 
with this phenotype in our GWA study of variations of >1% allele frequency [28]. For example, as 182 
summarized in Fig 1B, age at onset of European HD subjects with hap.01 (the major European disease 183 
haplotype, blue circles) is very similar to that of European HD subjects with hap.03 (blue triangles). 184 
Similarly, although based on a small number of samples, the most frequent Venezuelan haplotype 185 
hap.03 disease chromosomes (red triangles) did not appear to be consistently associated with earlier 186 
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age at onset compared to Venezuelan hap.01 disease chromosomes (red circles). These data suggest 187 
that the striking difference in age at onset between European HD and Venezuelan HD subjects is not 188 
likely to be due to a cis-factor on the hap.03 HTT haplotype.  189 
 190 
Full sequence analysis of the Venezuelan hap.03 HTT haplotype  191 
To more directly assess the possibility that the HD-associated Venezuelan hap.03 chromosome 192 
carries novel genetic variations in HTT that are responsible for earlier onset than in Europeans, we 193 
determined the HTT genomic sequence by whole genome sequencing of a representative nuclear 194 
Venezuelan HD family from Family 1 (S1 and S5 Figs), carrying hap.03 as the mutant haplotype. This 195 
nuclear family comprises 2 parents and 7 offspring (S5 Fig), so independently phased sequences of 196 
each trio (S6 Fig) were merged to define the consensus allele of the mutant HD chromosome at each 197 
site (Fig 2A). Except for some repeat regions and a small number of inconsistent sites (S6 Fig), the 198 
sequence analysis determined 99.02% of HTT bases of the Venezuelan hap.03 HD disease 199 
chromosome (Fig 2).  200 
Compared with the hg19 reference sequence (chr4:3066408-3255687; hg19 coordinates), the 201 
Venezuelan hap.03 disease chromosome carries alternative alleles at 28 variable sites, including a 202 
novel SNP (rs966032869 in intron 56) that was not described previously in public databases (Fig 2A). 203 
None of the variants at sites where Venezuelan hap.03 HD subjects carry non-reference alleles: 1) 204 
changes an amino acid, 2) is located in a splicing site, or 3) is associated with altered HTT mRNA 205 
expression levels (based on GTEx portal; https://www.gtexportal.org/home/). Additional Sanger 206 
sequencing analysis of HTT exon 1 revealed that the affected parent of this family (S5 Fig) carries a 207 
typical codon configuration in the polyglutamine/polyproline region consisting of 45 pure CAGs, 1 CAA, 208 
1 CAG, and downstream elements of 1 CCG, 1 CCA, 7 CCGs, and 2 CCT codons (Fig 2B). These data 209 
collectively add to the argument that variations at the HTT locus are not likely to underlie the earlier age 210 
at onset in the Venezuelan HD subjects and suggest that this difference from European HD subjects 211 
may instead be due to unknown Venezuela-specific genetic and/or environmental factors [32].  212 
 213 
The origin of the CAG expansion mutation 214 
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Our full sequence data provide an unprecedented opportunity to assess the origin of the CAG 215 
expansion mutation currently shared by most subjects in the Venezuela HD cluster. Consequently, we 216 
compared the full HTT sequence of the Venezuelan hap.03 HD chromosome to European hap.03 217 
disease chromosomes from HD subjects with Northern European, Spanish, and Portuguese ancestries 218 
(S7 Fig). The European hap.03 HD chromosomes do not differ from each other and are identical to the 219 
Venezuelan hap.03 HD chromosome at all but 2 sites: the novel SNP (rs966032869) and one 220 
annotated rare SNP (rs192188940) (S7 and S8 Figs). Interestingly, examination of these sites in a 221 
Brazilian HD subject carrying hap.03 revealed identity with the European hap.03, supporting an 222 
independent origin of the Venezuelan hap.03 HD chromosome.  223 
Next, we compared the Venezuelan HD hap.03 sequence to 1000 Genomes Project data 224 
(Phase 3) to identify normal control subjects who may have identical sequences. Among various 225 
populations in the 1000 Genomes Project data, including Africans, Ad Mixed Americans, East Asians, 226 
Europeans, and South Asians, only one Mexican individual (NA19774) has sequence identical across 227 
5864 comparable variation sites to the Venezuelan hap.03 disease chromosome, including at 228 
rs192188940 but excluding the novel SNP, rs966032869. The presence, but extreme rarity 229 
(MAF<0.001 based on UCSC Genome Browser) of rs192188940 on both normal chromosomes in the 230 
general population and on the Venezuelan hap.03 HD chromosome is most consistent with the CAG 231 
expansion mutation having occurred on a normal hap.03 chromosome that already carried the minor 232 
allele of this SNP. This normal chromosome may also have carried the rs966032869 minor allele or the 233 
latter may have arisen as a private mutation after CAG expansion. In any event, the most parsimonious 234 
explanation is that the major HD chromosome in the Venezuelan HD cluster arose by an ancestral CAG 235 
expansion event distinct from that associated with the common European hap.03 haplotype, potentially 236 
in an individual already geographically located in South America.  237 
 238 
Foundation for therapeutic strategies  239 
We recently reported for the major European HD haplotype, hap.01, that an allele-specific 240 
CRISPR/Cas strategy based upon pairs of PAM site-altering SNPs could be used to inactivate the 241 
mutant HTT allele while leaving the normal HTT allele intact [43]. To provide the basis for future 242 
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exploration of this potential therapeutic approach to benefit the Venezuelan HD population, we 243 
capitalized on the full sequence data to reveal variation sites suitable for mutant allele-specific silencing 244 
in this CRISPR/Cas strategy. Comparison to the haplotype most common in the normal population (i.e., 245 
hap.08 haplotype in 1000 Genomes Project, Phase 3 data) revealed Venezuelan hap.03-specific NGG 246 
CRISPR/Cas9 PAM-sites. For example, two CRISPR gRNAs depending on PAM-sites generated by 247 
rs2857935 and rs7659144 on the Venezuelan hap.03 would result in excision of the transcription start 248 
site and first two exons of the mutant gene, completely preventing generation of mutant HTT mRNA (S9 249 
Fig; red arrows). This sequence-based precision medicine strategy holds promise for HD and other 250 
dominant disorders [43], and the definition of CRISPR/Cas PAM sites specific to hap.03 ensures that if 251 
substantial social, political, logistical and financial hurdles are overcome the development and 252 
consequent benefit of completely allele-specific gene targeting treatment strategies need not be limited 253 
on scientific grounds to European populations but could be extended to the Venezuelan HD cluster. 254 
 255 
Identification of genetic modifiers of disease onset in the Venezuelan HD population 256 
Population stratification makes a genome-wide approach to identify genetic factors that are 257 
responsible for the earlier age at onset in combined Venezuelan and European HD subject cohorts 258 
problematic. However, the broad distribution of age at onset within the Venezuelan HD cohort does 259 
allow for statistical investigation of genetic modifiers present within this population using a GWA 260 
strategy. Consequently, we set out to identify genetic modifiers of HD in the Venezuela cluster by 261 
modeling residual age at diagnostic onset as a function of a SNP genotype and other covariates in 262 
linear mixed effect models to correct for familial relationships. Residual age at onset represents the 263 
difference between observed age at onset and expected age at onset predicted from CAG repeat size 264 
in this population (Fig 1B, red line), thus reflecting the degree of modification of onset age by factors 265 
other than CAG repeat size (S10 Fig). In a GWA analysis of 374 Venezuelan HD individuals (Fig 3; S11 266 
Fig), we observed one genome-wide significant modifier locus on chromosome 7 (Fig 4) and loci of 267 
suggestive significance on chromosomes 4 (S12A Fig) and 17 (S12B Fig). Considering the small 268 
sample size in our genetic analysis, detection of genome-wide significant signals was surprising, 269 
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although common modifiers may show stronger effect sizes than typical common disease risk alleles in 270 
GWA studies [28]. In any event, additional analyses argue against statistical inflation (S11 Fig).  271 
  272 
Population-specific modification signals 273 
Interestingly, the chromosome 7 locus that shows genome-wide significant association signals 274 
in the Venezuelan HD subjects (Fig 4A) was not significantly associated with residual age at onset in 275 
European HD subjects (Fig 4B). The same is true for suggestive significant loci on chromosomes 4 and 276 
17. The top SNP at the chromosome 7 locus, rs12668183, is associated with a -2.8 year effect size per 277 
minor allele in Venezuelan HD, but no effect in European HD subjects (Fig 4C; S13 Fig), indicating 278 
population-specific modification of HD. Intrigued by this, we performed genetic modification score 279 
analysis using a polygenic risk score method to compare these HD populations. Based upon 280 
association analysis results from European HD subjects [28], we constructed a polygenic modification 281 
scoring routine using effect sizes of 44 independent suggestive SNPs (p-value < 0.00001) and the 282 
number of effect alleles of scoring SNPs. Then the same scoring method was applied to the training set 283 
(European HD subjects) and the Venezuela test set to judge how well the European-based HD 284 
modification score explains phenotypic variance in the Venezuelan HD cluster. As anticipated, the 285 
European polygenic modifier score explained a significant amount of variation in residual age at onset 286 
among European HD subjects (S14A Fig; modifier score p-value < 2E-16; R-squared, 19.9%). 287 
However, the modification score did not explain the variance in residual age at onset in the Venezuelan 288 
HD subjects (S14B Fig; modifier score p-value, 0.75; R-squared, 0.03%). Consistent with the 289 
chromosome 7 modification signals, this difference may reflect a major contribution of population-290 
specific factors to modification of HD.  291 
The genetic modifier signals previously discovered on chromosomes 15, 8 and 3 in the larger 292 
European HD GWA study [28] were not detected in the Venezuela HD GWA sample (Fig 3). This is 293 
likely due to the reduced power of the much smaller Venezuela HD sample. Indeed, the association 294 
signals at those loci that were genome-wide significant in European HD subjects (both rare and 295 
common modifier signals) were modestly improved by adding Venezuelan HD subject data into the 296 
meta-analysis (Fig 5A), consistent with these known HD modifiers also acting to modify HD in 297 
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Venezuelans. For example, on chromosome 15, when meta-analysis was performed to combine 298 
European HD data and Venezuelan HD data, the overall association signals were improved, revealing 299 
the strongest modification signal at the SNP rs150393409, a predicted deleterious missense alteration 300 
in FAN1 that is likely to be the functional variant responsible for modification (Fig 5B). Effect sizes for 301 
this SNP were similar between the two populations (-6.4 and -5.5 years/minor allele, respectively) (Fig 302 
5C). Together, our association analysis results indicate that there may be both population-shared and 303 
population-specific modifying genetic factors that influence the rate of pathogenesis in HD.  304 
 305 
Venezuelan-specific modification signals on chromosome 7 306 
Focusing on the Venezuelan-specific modification signals on chromosome 7, the top SNP in this 307 
region, rs12668183, is common in all 1000 Genome Project populations with minor allele frequencies 308 
ranging from 30% in Europeans and 35% in the Ad Mixed Americans to 46% in East Asians. When 309 
SNPs in this region were conditioned by rs12668183, no SNPs remained significantly associated (Fig 310 
4D), indicating that the significant SNPs all tag a single modifier effect. The association signals were 311 
not contributed by CNV since the frequency of CNV in the region was very low (S15A Fig) and when 312 
samples carrying CNV were excluded from the analysis, association signals were virtually unchanged 313 
(S15B Fig). The association signals were not solely contributed by Family 1, since association analysis 314 
based separately on this family and on all other families as a group generated similar significance 315 
levels (S16 Fig), suggesting roughly equal contributions to the overall association signals. The 316 
association signals also were not due to skewing of the quantitative analysis by a few inaccurately 317 
phenotyped individuals since dichotomous analysis comparing allele frequencies of extreme residual 318 
age at onset groups was consistent with the continuous QTL GWA analysis result (S17 Fig). The 319 
associated SNPs tagged a single modifier haplotype at SOSTDC1 (Fig 4), which encodes a member of 320 
the sclerostin family (https://www.ncbi.nlm.nih.gov/gene/25928) that functions as a bone morphogenetic 321 
protein (BMP) antagonist, and plays a role in signaling during cellular proliferation, differentiation, and 322 
programmed cell death [44-47]. Each minor allele of the top SNP was associated with a hastening of 323 
onset by 2.8 years compared to those homozygous for the major allele. The most significant SNPs 324 
associated with HD age at onset are located just 3’ to SOSTDC1, and also show significant eQTL 325 
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(expression quantitative trait loci) signals for SOSTDC1 in the GTEx data set 326 
(http://www.gtexportal.org/home/eqtls/byGene?geneId=sostdc1&tissueName=All) (Fig 6) whereas none 327 
of these SNPs show evidence of association with expression of any of the other genes in the region. 328 
Interestingly, the minor alleles of SNPs most significantly associated with modification of HD onset are 329 
associated with reduced expression of SOSTDC1 in some GTEx tissues (e.g., ovary, artery-tibial, 330 
thyroid) (Fig 6A) but not with increased expression (Fig 6B). This relationship supports the hypothesis 331 
that the accelerated onset of HD caused by this modifier locus is due to reduced levels of SOSTDC1.  332 
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Discussion  333 
Investigation of haplotypes in HD subjects, including family members from the large Venezuelan 334 
HD cluster and many families from North America and Europe, originally permitted delineation of the 335 
chromosomal localization of the HD mutation [4-6,35], and ultimately led to identification of the cause of 336 
the disease [3]. The most frequent HTT haplotype on HD chromosomes, currently named hap.01 337 
[34,38,48] and defined by a standard panel of frequent SNPs, accounts for the largest proportion of HD 338 
subjects of European ancestry [34,37,38], but CAG expansions also occur on a variety of other 339 
haplotypes [33-38], indicating that multiple mutational events have produced HD and emphasizing the 340 
unstable nature of HTT CAG repeats [16,24,49,50]. The third most frequent HTT disease haplotype 341 
among HD subjects throughout Europe is hap.03. Consistent with our observation of a Brazilian subject 342 
with a hap.03 HD chromosome comparable to that in Northern European, Spanish and Portuguese 343 
subjects, HTT CAG expansion mutations of HD subjects in Latin America have been hypothesized to 344 
be of European origin [51]. However, sequence differences on the Venezuelan HD cluster hap.03 345 
disease chromosome are most consistent with an independent origin of their HD mutation, possibly due 346 
to CAG expansion in an individual in South America. With the full sequence of the Venezuelan HD 347 
chromosome now available, a finer definition of the origin of this disease mutation may ensue from the 348 
accumulation of more extensive genomic data from geographically defined normal populations. Similar 349 
studies of other geographically separated HD clusters could also provide further insights into how 350 
normal range CAG repeats expand into the disease-causing range, the emergence of new cases of HD 351 
and genetic anticipation.  352 
The discovery of the cause of HD made possible the generation of model systems [22] and 353 
numerous hypotheses regarding disease mechanisms have subsequently been raised [1,9]. However, 354 
many mechanism-based therapeutic targets that were highly efficient in animal models have turned out 355 
not to be effective in humans [52,53], perhaps due to species-specific differences in the effects of, or in 356 
the response to, the HD mutation or to the use of extreme CAG repeat lengths in most models. An 357 
alternative route to developing rational treatments is to capitalize on the genetic information that can be 358 
obtained from studies of human HD subjects. We have pursued two distinct directions in this regard, 359 
both of which are augmented by our findings concerning the Venezuelan HD cluster. The most readily 360 
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definable therapeutic target in HD is the mutant gene itself, since elimination of its expression would 361 
remove the factor that ultimately precipitates all aspects of the disease. Our previous sequence 362 
analysis of hap.01, the major European haplotype, enabled us to develop allele-specific CRISPR/Cas 363 
targeting strategies [38,43,48] to inactivate the mutant HTT allele without damaging the normal HTT 364 
allele, providing a novel route to developing a treatment. The full sequence of the Venezuelan hap.03 365 
HD chromosome and consequent definition of mutant allele-specific CRISPR/Cas9 PAM sites supports 366 
this same approach, ensuring that further therapeutic development of these allele-specific inactivation 367 
strategies need not be limited on scientific grounds to European HD subjects, but, if societal hurdles 368 
were overcome, could also benefit those in the Venezuelan HD cluster who have contributed so much 369 
to HD research. We have also reasoned that more traditional pharmaceutical development for HD could 370 
benefit from rational, in-human validated, therapeutic targets discovered by identifying genes that act to 371 
significantly modify disease pathogenesis in the subjects themselves. The well-established inverse 372 
relationship between CAG repeat length and age at clinical onset of HD pointed both to the CAG repeat 373 
size as the driver of the rate of HD pathogenesis and to a role for genetic and environmental factors in 374 
modifying the impact of the CAG repeat [7,15-18,30-32,54]. Our haplotype analyses indicated that other 375 
genetic variations at HTT are not a common source of HD modification [34], yet the variance in age at 376 
onset at any given repeat length is large and heritable, so we pursued a GWA analysis of subjects of 377 
European ancestry to discover significant unlinked modifiers of the age at clinical onset. The most 378 
significant locus hastens onset by approximately 6 years per rare allele demonstrating that quite strong 379 
modifier effects are possible in humans [28]. These modifier effects are due to naturally occurring 380 
variations in particular genes and pathways, and it can be expected that pharmaceuticals developed to 381 
target the same pathways could have even larger effects.  382 
Our initial European HD GWA analysis and follow-up study highlighted the importance of DNA 383 
maintenance/repair pathways in modifying the rate of CAG-dependent HD pathogenesis and suggested 384 
that somatic instability of the CAG repeat accelerates the disease [28,40]. While we saw some 385 
evidence that these processes also act to influence HD onset in Venezuela, a much stronger result 386 
from our unbiased genetic study of Venezuelan HD subjects points to a different modifier process. The 387 
genome-wide significant modification signals are focused at SOSTDC1 (sclerostin domain containing 1) 388 
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whose protein product functions as a bone morphogenetic protein (BMP) antagonist [46,55] and 389 
therefore negatively regulates BMP signaling. The expression of this gene is altered in various cancers 390 
[45,56-58]. The locus is also associated with lipid-lowering in response to statins [59] 391 
(https://www.ebi.ac.uk/gwas/), providing a clear example of a phenotype determined by gene-392 
environment interaction. 393 
Compared to European HD, the Venezuelan HD subjects display a similar CAG size/age at 394 
onset relationship, and full dominance of the longest CAG allele, but at equivalent CAG sizes, they 395 
develop motor symptoms earlier, suggesting the potential for population-specific genetic or 396 
environmental influences that accelerate HD pathogenesis. Our GWA analysis appears to have 397 
detected one such locus, whose combination of high allele frequency (38%) and large effect size 398 
(almost 3 years earlier onset per minor allele) made it detectable at genome-wide significance in only a 399 
few hundred Venezuela subjects. Population-specific modifiers of a disease have been reported only 400 
rarely in the literature [60] but examples of population-specific disease risk association are reported 401 
frequently [61-67]. Population-specific studies can therefore provide deeper insights into genetic 402 
architecture of human traits and diseases, although the relative contribution of population-specific 403 
variants, gene-gene interactions and gene-environment interactions has not been fully assessed. The 404 
fact that the chromosome 7 HD modifier locus does not yield evidence of modification in European HD 405 
suggests that the modifier effect is due either to a Venezuela-specific functional variant at the locus or 406 
to interaction of the locus with some genetic or environmental feature specific to the Venezuelans. 407 
Assessment of the former possibility will require detailed sequence comparison and functional 408 
dissection of the locus, but the observation that the top SNPs are also associated with reduced 409 
expression of SOSTDC1 in non-Venezuela data suggests that the second alternative is also worthy of 410 
consideration. Our data are consistent with the possibility that reduced expression of SOSTDC1 in 411 
individuals carrying the chromosome 7 modifier haplotype interacts with a population-specific factor to 412 
modify HD in Venezuela. A role for shared environmental factors in influencing age at onset in the 413 
Venezuelan HD cluster has been proposed previously [32] and in an initial assessment of potential 414 
genetic interaction involving the chromosome 7 locus, we detected suggestive signals (S18 Fig) that 415 
might reflect functional genetic interaction. Identification of the Venezuela-specific factor at the 416 
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chromosome 7 locus, at an interacting locus, or in the environment that contributes to the modifier 417 
effect could yield insight into the mechanism of HD and provide another route to treatment that might be 418 
applicable in both the Venezuelan and other HD populations. Interestingly, SNPs whose alternative 419 
alleles are associated with increased levels of SOSTDC1 have much lower allele frequencies among 420 
our study subjects, potentially explaining the failure to yield significant signals in the modifier GWA. 421 
However, those alleles do show trends toward positive modification, implying that increased levels of 422 
SOSTDC1 may delay age at onset in this population. From this perspective, identification of factors that 423 
induce increased levels of SOSTDC1 may also have therapeutic utility.  424 
In summary, our comprehensive genetic investigation of a distinct disease population has 425 
revealed intriguing aspects of HD, which are directly relevant for gene-based and traditional target-426 
directed small molecule therapeutic development, both for this population and potentially for HD more 427 
generally.  428 
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Methods 429 
Ethics Statement 430 
The study was approved by the Partners HealthCare Institutional Review Board as Protocol #: 431 
2009P000566/PHS, “Genetic Variation that Modifies HD Phenotype” and performed on DNA samples 432 
deposited previously, based upon oral consent, into a Partners HealthCare Institutional Review Board 433 
approved repository (currently Protocol# 2010P001611/PHS, “CHGR Neurodegenerative Repository”).  434 
 435 
Subjects, genotyping, quality control analysis, and genotype imputation 436 
In a study approved by the Partners HealthCare Institutional Review Board, the Genetic 437 
Modifiers of HD (GeM-HD) Consortium carried out genotyping for 3,447 HD subject samples from the 438 
Massachusetts Huntington’s Disease Center without Walls repository, which included banked samples 439 
from North American, European and Venezuelan families who had previously donated blood samples 440 
for HD research, and from the European Huntington's Disease Network (EHDN) Registry study [68]. 441 
Data from Illumina Omni2.5 arrays were generated at the Broad Institute and European HD subjects 442 
from this dataset (namely, HD GWA3) were analyzed with previous HD GWA data in order to identify 443 
genetic modifiers of HD in Europeans [28]. 549 subjects from the Venezuela HD cluster, described in 444 
Wexler et al., 2004 [30], were excluded from the previous analysis due to ancestry, and these form the 445 
primary population investigated in this study. As previously described [28], we applied quality control 446 
(QC) metrics such as SNP call rate >95%, minor allele frequency (MAF) >1%, Hardy-Weinberg 447 
equilibrium p-value >1E-6, sample call rate >95% to prepare high quality genotype data (538 subjects). 448 
Ancestry of samples was confirmed by principal components analysis using the PLINK program [69]; 449 
MDS (multidimensional scaling) values of study subjects were compared to those of 1000 Genome 450 
Project samples. Familial relationships were determined based on pair-wise IBD (identity-by-descent) 451 
estimation using the PLINK program and compared with existing pedigree charts from the U.S.-452 
Venezuela Collaborative Research Project [32]. For a given individual, all related individuals with PLINK 453 
PI_HAT value greater than 0.125 were identified, and grouped into a family. Subsequently, we checked 454 
if the rest of samples were related to any of members of that family based on the same PI_HAT value 455 
criteria, and newly discovered related individuals were merged with previously defined family. These 456 
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procedures were repeated exhaustively to identify all related subjects, generating 22 families with 457 
variable sizes. Therefore, an individual within a given re-constructed family is related to at least one 458 
other subject. Since we used estimated IBD values in identifying relatives to re-construct families, some 459 
families may have somewhat distantly related members. Haplotype phase of study subjects was based 460 
on computational phasing of 21 tagging SNPs [34,38], generating the names of haplotypes for each 461 
individual (e.g., hap.01 - hap.16). Since all HD subjects in each family share the same ancestral HD 462 
disease haplotype, the most frequent haplotype in the family was assigned as the HD disease 463 
chromosome haplotype. Genotype imputation was performed by the Michigan Imputation Server 464 
(https://imputationserver.sph.umich.edu/index.html) using the 1000 Genomes Project mixed population 465 
as a reference panel. The SHAPEIT phasing program 466 
(https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html) was used for pre-phasing study 467 
samples. The same QC parameters were applied to imputed data to ensure the quality of genotype 468 
data.  469 
 470 
CAG repeat size, age at onset of motor symptoms of HD, and residual age at onset 471 
phenotype for genetic analysis 472 
Methods to determine the sizes of HTT CAG repeats for each Venezuelan study subject are 473 
described elsewhere [70]. Age at onset was determined either prospectively or retrospectively based 474 
upon examination of subjects by experienced neurologists as described by the U.S.–Venezuela 475 
Collaborative Research Project [32]. Regression modeling analysis was performed to describe the 476 
specific relationship between age at onset and CAG repeat size in these Venezuelans. Briefly, natural 477 
log transformed age at onset of Venezuelan HD and European HD were modeled as a function of the 478 
size of expanded CAG repeat; study population-specific intercepts were estimated by including a 479 
covariate specifying individual population in the regression model. When a HD subject carries two 480 
expanded alleles (CAG > 35), the longer one was used because of complete dominance [7]. This 481 
regression model described the overall relationship between CAG and age at onset, and still permitted 482 
the revelation of any differences between Venezuelan HD and European HD. Using this regression 483 
model, predicted age at onset was estimated based on CAG repeat size, and subsequently was 484 
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subtracted from actual age at onset to calculate residual age at onset for each HD individual. Residual 485 
age at onset represents how early or late a HD subject develops motor symptoms compared to 486 
expectation based on his or her expanded CAG repeat length. A positive residual age at onset means 487 
an HD individual developed symptoms later than expectation, and a negative residual age at onset 488 
means an HD individual developed symptoms earlier than expectation.  489 
 490 
Whole genome sequencing and phasing  491 
For a selected nuclear family, where the HD mutation was transmitted on the hap.03 haplotype, 492 
we performed whole genome sequencing analysis as described previously [48]. Sequencing was 493 
performed by Complete Genomics, generating variant calling files containing sequence variants with 494 
confidence scores. Since we aimed at maximizing SNP discovery and the inclusion of related samples 495 
provided the opportunity to assess sequencing errors, we examined all variants originally reported by 496 
Complete Genomics. For this study, we focused on a genomic region (chr4:3066408-3255687; hg19 497 
coordinates). Haplotype phasing was performed by using father-mother-child trio data as summarized 498 
in S5 Fig. Seven trios with a HD parent, normal spouse and HD child were defined in this family, and 499 
therefore the same parents were members of 7 trios, but data pre-processing and trio phasing was 500 
performed for each trio independently. Briefly, a variant site was excluded in a given trio if 1) genotypes 501 
in all 3 individuals were unknown, 2) all 3 individuals were identically heterozygous or 3) a Mendelian 502 
error was detected. Since we aimed at maximizing variation coverage, we included sites with partially 503 
missing data even though this makes detection of Mendelian errors difficult. Thus, Mendelian error 504 
detection was based on checking the genotype data for the following: 1) variant sites without any 505 
missing data, 2) sites with no missing data in the child and one or two alleles missing in only one 506 
parent, and 3) sites with one allele missing in the child and none missing in parents. This detection 507 
pipeline could still miss certain Mendelian errors due to missing genotypes, but these errors could be 508 
further identified by subsequent merging of multiple phased haplotypes in the family. After removing 509 
sites with Mendelian errors, sites that could not be confidently phased due to missing genotypes, and 510 
sites heterozygous in all 3 members of the trio, we phased the alleles at all remaining sites to produce 511 
fully phased hap.03 disease haplotype for each trio.  512 
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After data pre-processing, trio genotype data were phased using the BEAGLE program 513 
(https://faculty.washington.edu/browning/beagle/beagle.html), and the HD disease chromosome 514 
haplotypes were further analyzed. One hap.03 disease chromosome haplotype, inherited from the 515 
father, was obtained for each of the seven trios, and we merged these to discover any inconsistent 516 
alleles for additional QC analysis. Locations and numbers of Mendelian errors and inconsistent alleles 517 
are summarized in S6 Fig. We then finalized the hap.03 disease haplotype by 1) taking alleles for sites 518 
with at least two phased allele calls, 2) assigning ‘N’ for sites that were unphaseable, or had missing 519 
genotype or Mendelian errors, and 3) assigning ‘?’ for the inconsistent sites. These procedures yielded 520 
phased haplotypes covering 99.02% of the sites in the region. A novel SNP variation was identified, 521 
and submitted to dbSNP Build 150 (rs966032869). 522 
 523 
Capture sequencing analysis of Venezuelan and European HD subjects 524 
In order to validate Venezuelan HD whole genome sequencing data and compare to the hap.03 525 
disease chromosome in European HD subjects, we performed capture sequencing for an additional 8 526 
Venezuelan HD subjects and 7 unrelated European HD subjects. Haplotypes of disease and normal 527 
chromosomes were based on computational phasing [34] of our GWA samples [28]. Capture probes 528 
were designed to enrich the target region chr4:3066408-3255687 (hg19 coordinates) using the Agilent 529 
SureDesign online tool. This generated ultra-long 120-mer biotinylated complementary RNA baits, and 530 
these capture probes were used for solution-based SureSelect target enrichment. Briefly, genomic 531 
DNAs were sheared to produce smaller fragments and libraries prepared with sequencer specific 532 
adaptors and indexes for multiplexing. DNA libraries were hybridized with biotinylated cRNA baits, 533 
which were complementary to regions of interest. The bait-library complexes were pulled down by 534 
magnetic beads. After the beads were washed, the RNA bait was digested to obtain the target DNA of 535 
interest, and subjected to sequencing using Illumina HiSeq 100bp paired-end sequencing at the Broad 536 
Institute. Sequence reads were aligned for variant calling using the Genome Analysis Toolkit Best 537 
Practices workflow (https://software.broadinstitute.org/gatk/). Additional genotyping for specific sites 538 
was performed by conventional Sanger sequencing. 539 
 540 
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Genome-wide association analysis, conditional analysis, and extreme dichotomous 541 
analysis 542 
Residual age at onset was modeled by SNP, gender, and ancestry covariates (i.e., MDS 1-4) in 543 
a linear mixed effect model based on kinship matrix using the GEMMA program 544 
(http://www.xzlab.org/software.html). We applied an additive model for each SNP whose minor allele 545 
frequency is greater than 5% in the study population. GWA analysis using imputed genotypes revealed 546 
genome-wide significant SNPs at a locus on chromosome 7. Subsequently, we compared genotypes 547 
(chr7: 16150000-16815000, hg 19) of 5 Venezuelan HD individuals who had both sequence and 548 
imputed genotype data, revealing a mean concordance rate of 98.7% (range, 98.2 ~ 99.3%).  549 
Genomic inflation factor was calculated using the GenABEL package (median method) 550 
(http://www.genabel.org/manuals/GenABEL). Recombination rate was obtained from HapMap data 551 
(http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html), and plotted on the secondary Y-552 
axis of regional association plots. In order to determine dependency of SNPs in a given region, linear 553 
mixed effect models were constructed similarly but included the most significant SNP as a covariate. 554 
Significances of SNPs in the ordinary association analysis were compared to those in conditional 555 
analysis. Also, we performed extreme dichotomous analysis to determine whether a small number of 556 
data points drove the significant association. We directly compared SNP allele frequencies of those 557 
individuals whose residual age at motor onset was among the 10% extremes of earlier and later than 558 
expected onset. Logistic regression analysis was performed using the GEMMA program. 559 
 560 
CNV analysis, meta-analysis, and polygenic modification score analysis 561 
Genome-wide copy number variation was determined from GWA data using PENNCNV 562 
program (http://penncnv.openbioinformatics.org/en/latest/). For chromosome 15 region, we meta-563 
analyzed association analysis results of Venezuelan HD and European HD using the METAL program 564 
(https://genome.sph.umich.edu/wiki/METAL_Documentation). In order to determine whether a 565 
polygenic modification score based on European HD subjects captured individual deviation from the 566 
expected age at onset for a given CAG size in Venezuelan HD, we obtained effect sizes and 567 
significances of SNPs based on the European HD subjects. Polygenic modification score is defined as 568 
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the sum of effect allele count X effect size for each HD subject. We used independent SNPs with 569 
suggestive significance (p-value < 0.00001). This scoring method was applied to European HD and 570 
Venezuelan HD to calculate individual modification score. Subsequently, polygenic modification score 571 
was used as the independent variable with gender and ancestry covariates to explain residual age at 572 
onset in each population.  573 
 574 
GTEx eQTL analysis 575 
For SNPs in the chromosome 7 region, we evaluated the significance of eQTL with genes in the 576 
region using the GTEx portal data base (http://www.gtexportal.org/home/). Among ISPD, SOSTDC1, 577 
and LRRC72, ISPD and SOSTDC1 generated significant eQTL signals in GTEx data set, and therefore 578 
these SNPs were downloaded for subsequent analysis. 42 and 231 SNPs (non-unique) were 579 
significantly associated with expression of ISPD and SOSTDC1 in various human tissues, respectively. 580 
For those significant eQTL SNPs, we compared the significance (-log10(p-value)) in our modifier 581 
association analysis to those in GTEx cis eQTL analysis, revealing a correspondence between GWA 582 
significance and eQTL significance only for SOSTDC1.  583 
 584 
Potential genetic interaction with chromosome 7 modifier locus 585 
Venezuelan HD subjects were separated into two groups based on chromosome 7 modifier 586 
genotype (rs12668183), resulting in rs12668183-carriers and non-rs12668183-carriers. For each group 587 
of Venezuelan HD subjects, independent GWA analysis was performed. In order to reduce outlier 588 
effects in the continuous analysis, subjects were sorted based on residual age at onset, and top and 589 
bottom 40% of subjects were analyzed using dichotomized phenotype data, focusing on comparing 590 
allele frequency differences between early and late onset groups. Mixed effect models were used to 591 
correct familial relationship.  592 
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Data Availability 593 
Original data are available on request. Please direct inquiries to info@chdifoundation.org with the 594 
words ‘‘VZ2018 data’’ in the subject line. 595 
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Figure Legends 788 
Figure 1. Earlier age at onset in HD subjects in Venezuela.  789 
(A) We evaluated the relationship between age at motor onset and the longer CAG repeat using the 790 
QC-passed data set. Age at onset and the longer CAG repeat of HD homozygotes are indicated in 791 
open red symbols (12 individuals).  792 
(B) Age at onset of motor signs was plotted against the size of expanded CAG repeat for HD subjects 793 
with European ancestry (blue) and Venezuelan HD subjects (red). Subsequently, log transformed age 794 
at onset (natural log) was modeled as a function of CAG repeat length for each population in a linear 795 
regression model. Then, fitted values were transformed back into natural scale age at onset for plotting. 796 
Blue and red lines represent regression models for European and Venezuelan HD, respectively. In 797 
addition, for a given CAG repeat size, the average of age at onset of HD subjects carrying a hap.01 798 
disease haplotype (circle) or a hap.03 disease haplotype (triangle) are marked.  799 
(C) Disease duration data were compared between European and Venezuelan HD subjects. Duration 800 
values were available for 645 European HD and 85 Venezuelan HD subjects. Means of duration were 801 
15.4 and 15.7 for European and Venezuelan HD subjects, respectively (Wilcoxon test p-value=0.2783).  802 
 803 
Figure 2. Sequence of hap.03 mutant haplotype. 804 
(A) Based on consensus alleles in 7 phased haplotypes in the sequencing family, the hap.03 disease 805 
haplotype sequence was reconstructed at the nucleotide level. Alleles on hap.03 that are different from 806 
the reference allele are shown with their genomic locations relative to HTT refseq NM_002111. The 807 
previously reported sequence of hap.01 is also displayed. D, I and N represent deletion, insertion, and 808 
missing, respectively.  809 
(B) The region containing the CAG repeat was missing in the sequencing data due to difficulty in 810 
aligning repeats. Thus, we performed additional Sanger sequencing to determine the sequence of the 811 
HTT CAG repeat region and found that the transmitting HD parent has a typical repeat sequence and 812 
downstream elements: uninterrupted 45 CAG repeats, 1 CAA, 1 CAG, 1 CCG, 1 CCA, 7 CCG, and 2 813 
CCT, comparable to the structure seen on the most frequent HD hap.01 chromosome in Europeans.  814 
 815 
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Figure 3. Genetic modifiers in Venezuelan HD subjects.  816 
Mixed effect linear regression analysis was performed for each SNP to determine the level of 817 
significance of the SNP in explaining the variance in residual age at onset in Venezuelans. SNPs that 818 
have minor allele frequency greater than 5% are shown, revealing genome-wide significant signals on 819 
chromosome 7. The X-axis and Y-axis represent chromosome and -log10(p-value), respectively. A 820 
dotted red horizontal line marks the level for genome-wide significance.  821 
 822 
Figure 4. Genome-wide significant modification signals on chromosome 7 in Venezuelan HD.  823 
Association analysis results in Venezuelan HD (A) and in European HD (B) are displayed for the 824 
chromosome 7 region. Each grey circle represents a SNP. Y-axis and X-axis represent significance (-825 
log10(p-value)) and genomic coordinate (hg19 assembly), respectively. Dotted red lines mark the level 826 
for genome-wide significance. Genes on the plus strand and negative strand are displayed in red and 827 
blue, respectively. Recombination rate based on HapMap data is shown as a blue trace (secondary Y-828 
axis).  829 
(C) For the top SNP in this region in Venezuelan HD analysis, allele frequency, effect size, and p-830 
values are shown for both Venezuelan HD and European HD.  831 
(D) In addition, a conditional analysis was performed focusing on the chromosome 7 region in 832 
Venezuelan HD subjects to determine whether a cluster of significant SNPs in this region tags a single 833 
modification signal. SNPs in this region were conditioned by the top SNP in the association analysis. Y-834 
axis and X-axis represent significance in the conditional analysis and original association analysis.  835 
 836 
Figure 5. Improvement of chromosome 15 association signals by addition of Venezuelan HD 837 
data.  838 
(A) GWA analysis results for European HD subjects were combined with those of Venezuelans in order 839 
to determine whether or not addition of Venezuelan data improved modification association signals. 840 
Association signals in Europeans (X-axis) and that in Europeans + Venezuelans (Y-axis) are plotted. 841 
Open grey circles, which are above the red diagonal line, represent SNPs whose significance in 842 
association analysis was improved when European and Venezuelan data were combined.  843 
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(B) A regional association plot was generated focusing on chromosome 15, revealing that 844 
rs150393409, which specifies an arginine to histidine missense alteration predicted to be deleterious to 845 
FAN1, is the most significant SNP in this region.  846 
(C) A summary table is shown focusing on the top SNP in European + Venezuelan HD analysis.  847 
 848 
Figure 6. A potential role for reduced SOSTDC1 expression levels in HD onset modification.  849 
Modifier-associated SNPs in the chromosome 7 region were checked for association with expression 850 
levels of SOSTDC1. The Y- and X-axes represent significances in GTEx eQTL and modification in our 851 
GWA analysis, respectively. Panel A shows SNPs whose minor alleles are associated with decreased 852 
expression levels of SOSTDC1. Panel B shows SNPS whose minor alleles are associated with 853 
increased expression levels of SOSTDC1. 854 
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Supporting information 855 
S1 Fig. Ancestry characteristics of Venezuelan HD subjects.  856 
In order to confirm ancestry of Venezuelan HD study subjects, principal components analysis using 857 
genome-wide SNP data of samples was performed together with 1000 Genomes Project data (Phase 858 
3; 2,504 samples from 26 populations). The first vs. second MDS (multidimensional scaling) values (top 859 
row), and the third vs. fourth MDS values (bottom row) were plotted. 1000 Genomes Project samples 860 
are represented by colored symbols (A and B), or open grey symbols (C, D, E, and F). Study subjects 861 
used for GWA analysis (C and D) or sequencing analysis (E and F) are indicated by open black 862 
squares. For detailed description of populations and symbols of 1000 Genomes Project, refer to 863 
http://www.internationalgenome.org/faq/which-populations-are-part-your-study/. 864 
 865 
S2 Fig. Familial relationships of study subjects.  866 
For QC-passed 374 Venezuelan HD study subjects analyzed in GWA analysis, familial relationships 867 
were inferred based on genome-wide genotype data. Pair-wise IBD (identity-by-descent) values were 868 
estimated by the PLINK program. From 374 unique study subjects, IBD values were estimated for 869 
69,751 meaningful pairs. The mean of PI_HAT value (indicative of IBD) was 0.0253 (A). Based on Z1 870 
and Z2 values from the PLINK IBD estimation, we identified 170 unique parent-child pairs comprising 871 
216 subjects (B, red rectangle). In addition, siblings and other relationships were also revealed (B).  872 
 873 
S3 Fig. Reconstruction of families based on genome-wide genotype data. 874 
Based on pair-wise IBD estimations, families were reconstructed. A pair of related individuals whose 875 
PLINK PI_HAT value was greater than 0.125 (representing first cousin or closer relationships) were 876 
combined, and this process was repeated exhaustively until all related individuals were combined, 877 
generating 22 families with variable sizes. Therefore, an individual within a given re-constructed family 878 
has at least one relative. Families were numbered arbitrarily and were separated by blue boundary line. 879 
The size of each family is provided in a parenthesis, and haplotype of HD disease chromosome is 880 
indicated in parenthesis after slash. Unrelated individuals (18) are at the bottom-right of the plot without 881 
family name. 882 
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 883 
S4 Fig. Descriptive statistics of Venezuelan HD study subjects.  884 
Following sample QC analysis, 374 Venezuelan HD subjects including 12 homozygote HD individuals 885 
were analyzed. Histogram plots show distributions of longer CAG repeats (A), shorter CAG repeats (B), 886 
and age at onset of motor symptoms (C). The means of longer CAG, shorter CAG, and age at onset of 887 
motor symptoms are 45.9 (A), 19 (B), and 35.5 (C), respectively.  888 
 889 
S5 Fig. HD nuclear family used for whole genome sequencing analysis.  890 
Nine subjects including one non-HD parent were used for whole genome sequencing. This family 891 
inherits the hap.03 haplotype on the mutant chromosome as the majority of Venezuelan HD subjects 892 
do. For each subject, haplotypes of mutant chromosome (red) and normal chromosome (black) are 893 
indicated. In addition, to determine the phased sequence of HTT in this family, we performed trio 894 
phasing for each trio comprising parents and a child. As indicated by "Trio #", 7 trios were used for 895 
phasing analysis. For each trio phasing a small number of Mendelian errors were detected. Diamond 896 
symbols were used for children to maintain confidentiality.  897 
 898 
S6 Fig. Summary of sequencing and phasing analysis of HTT locus.  899 
(A) For each trio, trivial phasing analysis was performed using the BEAGLE program, and 7 phased 900 
mutant chromosomes were merged to identify consensus alleles of hap.03 disease haplotype in this 901 
family. We detected 6 unique Mendelian error sites, 3,231 unphaseable sites due to missing data, and 902 
7 inconsistent sites. In total 99.02% of bases were determined. Examples of inconsistent sites are 903 
shown in panel B. N and D represent missing and deletion. 904 
 905 
S7 Fig. Venezuelan mutant hap.03-specific sequence variations.  906 
(A) Northern (filled blue circles) or Southern European HD subjects (filled purple and orange circles 907 
representing Spanish and Portuguese HD, respectively) carrying hap.03 as the mutant chromosome 908 
were identified using phased haplotypes of GWA data. A scatter plot shows MDS 1 and 2 values from 909 
principal components analysis of GWA data relative to control populations such as CEU and TSI.  910 
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(B) Consensus alleles of the hap.03 haplotype in Venezuelan HD were obtained from trio phasing of 911 
family samples. In addition, consensus alleles of the hap.03 disease haplotype in 7 independent 912 
Northern European HD subjects were obtained from capture sequencing analysis (7 samples). Direct 913 
comparisons of consensus alleles revealed 2 sites (including a novel SNP) where alleles are different 914 
between Venezuelan and European hap.03 disease haplotypes. For the known SNP site 915 
(rs192188940), imputed GWA data for Spanish (15 samples) and Portuguese HD (43 samples) with 916 
hap.03 haplotype are also indicated. Since the novel SNP is not part of the 1000 Genomes Project 917 
reference panel, rs966032869 was not imputed in GWA data. 918 
 919 
S8 Fig. Validation of Venezuelan HD-specific variation sites.  920 
Sanger sequencing analysis was performed to validate the genotypes of Venezuelan hap.03-specific 921 
SNPs including a novel SNP. A panel of hap.03 HD subjects from Northern Europe (1 sample), Spain 922 
(4-6 samples), Portugal (4-6 samples), and Brazil (1 sample) were sequences, and representative 923 
sequencing analysis results are shown. 924 
 925 
S9 Fig. Allele-specific CRISPR/Cas9 target sites for Venezuelan HD subjects carrying mutant 926 
hap.03 haplotype.  927 
Fully reconstructed Venezuelan hap.03 sequences were compared to consensus allele of hap.08 allele 928 
from 1000 Genomes Project data (phase 3). Haplotype hap.08 represents the most common normal 929 
chromosome in Europeans and Americans (1000 Genomes Project, phase 3). A consensus sequence 930 
of hap.08 from the 1000 Genomes Project data represents the most frequent allele for a given site. 931 
Subsequently, we determined those PAM-altering SNPs that create and eliminate CRISPR/Cas9 PAM 932 
sites (NGG) in hap.03 and hap.08 haplotypes, respectively. In the region, 16 variations create NGG 933 
PAM sites only in hap.03 and therefore can be used for allele-specific CRISPR/Cas9 targeting aiming 934 
at silencing the mutant allele. Red arrows show an example where simultaneous application of CRISPR 935 
gRNAs is expected to selectively eliminate the transcription start site and expanded CAG repeat in the 936 
mutant HTT. 937 
 938 
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S10 Fig. Distribution of residual age at onset in Venezuelan HD subjects.  939 
In order to generate phenotype data for GWA analysis aiming at discovering modifiers of HD subjects in 940 
Venezuela, a regression model described in Fig 1B was used to calculate the difference between 941 
observed age at onset and predicted age at onset based on CAG repeat size. Distributions of residual 942 
age at onset in Venezuelans were visually compared that in European HD subjects previously 943 
described. The mean and median of residual age at onset in Venezuelan HD were 0.368 and 0.403, 944 
respectively. 945 
 946 
S11 Fig. Quantile-quantile (QQ) plot.  947 
Levels of genomic inflation were assessed based on QQ plot. The inflation factor was 1.0197 by the 948 
median method.  949 
 950 
S12 Fig. Suggestive association signals on chromosomes 4 and 17.  951 
Suggestive modification signals on chromosome 4 (A) and 17 (B) are displayed. X-axis and Y-axis 952 
represent genomic coordinate (hg19) and -log10(p-value), respectively. Each grey circle is a SNP, and 953 
cyan trace represents recombination rates (secondary Y-axis) based on HapMap data. All exons were 954 
combined to represent a gene, in red or blue to represent genes on plus and minus strand, 955 
respectively.  956 
 957 
S13 Fig. Population-specific modification by rs12668183 on chromosome 7.  958 
Residual age at onset of HD subjects carrying 0, 1, or 2 minor alleles of the top SNP (i.e., rs12668183) 959 
are plotted for Venezuelan HD (A) and European HD subjects (B). Red horizontal lines represent mean 960 
residual age at onset.  961 
 962 
S14 Fig. Genetic modification score based on European HD subjects.  963 
Independent suggestive significant or higher SNPs in European HD subjects were used as a training 964 
set to construct the polygenic modification score of each HD subject. Briefly, for a given individual, 965 
effect sizes of SNPs were multiplied by the number of effect alleles to calculate the sum of the 966 
 37
modification score. The same scoring method was applied to European HD subjects to estimate the 967 
maximum prediction power of the modification score (A). Next, the effect sizes and scoring SNPs based 968 
on European HD subjects were applied to calculate the genetic modification score of Venezuelan HD 969 
subjects and subsequently used to explain residual age at onset of Venezuelan HD subjects (B). For 970 
each HD population, residual age at onset was modeled as a function of genetic modification score to 971 
judge its significance.  972 
 973 
S15 Fig. Lack of contribution from CNV.  974 
(A) Focusing on the chromosome 7 region that generated genome-wide significant modification signals 975 
in Venezuelan HD, frequencies of CNVs are plotted over SNP association analysis results (grey 976 
circles). Black, blue, and red lines represent all CNVs, duplication, and deletion, respectively. Primary 977 
and secondary Y-axes represent SNP significances and frequencies of CNVs, respectively. X-axis 978 
represent genomic coordinate based on hg19 assembly. 979 
(B) In order to judge the levels of contribution of CNV to significant modification signals in the 980 
chromosome 7 region, samples carrying CNVs were excluded for SNP association analysis in a mixed 981 
effect model. X-axis and Y-axis represent association analysis results using all samples (374 subjects) 982 
and those using samples w/o CNVs (317 subjects). Significance means -log10(p-value).  983 
 984 
S16 Fig. Equal contribution from the main family and other families.  985 
In order to determine whether the genome-wide significant modification signals were largely contributed 986 
by the main family, we split the data into the main family (218 subjects) and other families (156 987 
subjects). Subsequently, statistical analysis was performed to determine whether residual age at onset 988 
in the main family was significantly different from that in the other families (A).  989 
(B) Chromosome 7 top SNP (i.e., rs12668183) was also analyzed independently in the two groups to 990 
assess the significance in modification.  991 
 992 
S17 Fig. Extreme dichotomous analysis.  993 
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As a confirmatory analysis of continuous phenotype data analysis, we performed extreme dichotomous 994 
analysis. Instead of using continuous residual age at onset data, we generated two groups representing 995 
the 10% extremes of age at onset. We then compared allele frequency of the markers between the 996 
extreme early onset group and the extreme late onset group. The X-axis represents continuous 997 
association analysis results using all samples, and Y-axis represents extreme dichotomous association 998 
analysis.  999 
 1000 
S18 Fig. Potential genetic interaction with chromosome 7 modifier. 1001 
We attempted to detect genetic interactions with chromosome 7 modifier locus. Venezuelan HD 1002 
subjects were grouped by a chromosome 7 modifier SNP rs150393409; minor allele-carriers (A; 238 1003 
subjects) and non-carriers (B; 136 subjects). For each group, samples with top and bottom 40% 1004 
residual age at onset were identified. Subsequently, GWA analysis was performed using dichotomized 1005 
phenotype data in mixed effect model (see method section). Although not genome-wide significant, 1006 
some regions in the genome suggested modification of HD in the presence (e.g., chromosome 8 in 1007 
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